Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy (scientific article)

Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response

Q45745304

Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy.

Q45762642

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

Q47832232

Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy

Q48676578

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study

Q82709302

Value of MRI as a surrogate marker for PML in natalizumab long-term therapy

Q83363676

Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS

Q83386697

Asymptomatic reactivation of JC virus in patients treated with natalizumab

Q94952126

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Q28243804

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section

Q30613846

Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs

Q30637358

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy

Q30689194

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

Q34275329

Asymptomatic reactivation of JC virus in patients treated with natalizumab

Q34801034

Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

Q35609239

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy

Q35675602

Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants

Q36974688

JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab

Q37085051

Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA.

Q37196796

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients

Q37206687

Changes to anti-JCV antibody levels in a Swedish national MS cohort

Q37267644

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

Q37714089

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Q37778944

Progressive multifocal leukoencephalopathy after natalizumab discontinuation

Q42255115

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis

Q42268433

Interpretation of positive molecular tests of common viruses in the cerebrospinal fluid

Q42269759

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

Q42648662

Discrepant findings in immune responses to JC virus in patients receiving natalizumab

Q42921605

A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology

Q43625138

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

Q43881574

Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?

Q43897444

Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors

Q44259807

Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid

Q44305650

Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies

Q44417521

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

Q44887406

An assay to quantify species-specific anti-JC virus antibody levels in MS patients

Q45352744

The effect of plasma exchange on serum anti-JC virus antibodies

Q45353518

Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.

Q45363437

P433

issue

P921

main subject

cerebrospinal fluid

Q54196

antibody

Q79460

progressive multifocal leukoencephalopathy

Q704930

P304

page(s)

792-801

P577

publication date

2014-05-08

P1433

published in

Annals of Neurology

Q564414

P1476

title

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy

P478

volume

Reverse relations

cites work (P2860)

Q38801394	45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches
Q36484448	Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
Q45334987	Anti-JC virus antibody testing for natalizumab-induced progressive multifocal leukoencephalopathy: Where are we and where should we go?
Q40565210	Anti-JC virus seroprevalence in a Finnish MS cohort.
Q52659119	Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Q26770664	B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions
Q36764988	Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy
Q36073992	Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab
Q38760860	Disease-modifying therapies and infectious risks in multiple sclerosis
Q30815289	Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases
Q90286881	Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
Q55020429	Estimation of intrathecal IgG synthesis: simulation of the risk of underestimation.
Q42560354	Finger pointing to JC virus: a tale of two indexes
Q51100906	High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - Commentary.
Q34818048	Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
Q38367755	Immunology of progressive multifocal leukoencephalopathy.
Q39039495	Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics
Q35078693	Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan.
Q40619670	MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance
Q41745436	MRI pattern in asymptomatic natalizumab-associated PML.
Q42181572	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.
Q38786252	Natalizumab in relapsing-remitting multiple sclerosis
Q39048568	Natalizumab treatment of multiple sclerosis: new insights
Q26781389	Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
Q52587612	Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
Q37475542	Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
Q38577593	Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).
Q102220458	Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease
Q28083338	Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate
Q58566596	Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy
Q92700314	Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient
Q26780412	Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
Q64118832	The Cerebrospinal Fluid in Multiple Sclerosis
Q45325710	The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Q97530876	Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod
Q52855510	[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].
Q85634787	[Prognostic and predictively relevant factors for multiple sclerosis]
Q88533703	[Progressive multifocal leukoencephalopathy]